MK-4827 (Niraparib)

Catalog No. A11026

MK-4827 is a novel potent, orally bioavailable PARP-1 and PARP-2 inhibitor.
  • Bian C, .et al. NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression, Nat Commun, 2019, Feb 11;10(1):693 PMID: 30741937
  • Tahira Baloch, .et al. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1, BMC Cancer, 2019, Jan 10;19(1):44 PMID: 30630446
  • Khalid Hilmi, .et al. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair, Sci Adv, 2017, May; 3(5): e1601898 PMID: 28560323
Catalog Num A11026
M. Wt 320.4
Formula C19H20N4O
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 1038915-60-4
Synonyms MK4827
SMILES C1C[[email protected]](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
MK-4827 is a novel potent, orally bioavailable PARP-1 and PARP-2 inhibitor.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 31.21 mL 156.05 mL 312.11 mL
0.5 mM 6.24 mL 31.21 mL 62.42 mL
1 mM 3.12 mL 15.61 mL 31.21 mL
5 mM 0.62 mL 3.12 mL 6.24 mL

*The above data is based on the productmolecular weight 320.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.